Azenta, Inc. provides life sciences solutions focused on cold-chain sample management, automated storage, consumables, informatics, repository services and multiomics offerings. Its updates commonly cover the Sample Management Solutions and Multiomics businesses, including genomic services, gene synthesis execution, sample storage, high-throughput processing and branded products such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro and Barkey.
Azenta news also includes quarterly operating results, guidance updates, long-range planning, governance and leadership changes, customer and research partnerships, and acquisition activity. The completed acquisition of UK Biocentre expanded the company’s sample management, sample storage and processing capabilities in the United Kingdom and added a European operational hub for its Sample Repository Services business.
Azenta (Nasdaq: AZTA) announced its participation in the Jefferies Global Healthcare Conference in New York on June 5, 2024. The company's presentation will start at 11:00 am ET. A live webcast and a replay will be accessible on Azenta's investor relations website. This event is significant for sharing strategic updates and potential investor engagement.
Azenta has inaugurated a new Genomics Laboratory in Oxford, UK, enhancing its global GENEWIZ Multiomics & Synthesis Solutions. This facility provides UK researchers with advanced NGS platforms and local scientific expertise. The lab aims to expedite high-quality data delivery, fostering progress in critical research areas like diabetes, infectious diseases, and Alzheimer's. The lab features state-of-the-art technology from Illumina, PacBio, Oxford Nanopore, and more. It offers a comprehensive suite of services including library preparation, sequencing, and bioinformatics, supported by Ph.D.-level managers. The opening event on April 25, 2024, included a ribbon-cutting ceremony and lab tour.
Azenta, Inc. (Nasdaq: AZTA) announced a CEO succession plan with CEO Dr. Stephen Schwartz retiring after over 14 years of service. The Board is actively searching for a successor with the help of a leading executive search firm. Dr. Schwartz expressed pride in Azenta's transformation into a leading life sciences business and supports a smooth transition to the new CEO. Azenta also reported its earnings results for the second quarter of fiscal 2024.
Azenta, Inc. (Nasdaq: AZTA) reported financial results for Q2 fiscal 2024 with revenue of $159 million, up 7% YoY. Positive free cash flow for the fourth consecutive quarter. Strong organic revenue growth in Sample Management Solutions and B Medical Systems. Operating loss of $147 million, with operating margin at (92.3%). Non-GAAP diluted EPS improved to $0.05. Cash balance of $975 million. Share repurchase program ongoing. Lowered revenue guidance for FY2024 but raised earnings guidance.
Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2024 earnings on May 8, 2024, after market close. The Company will hold a conference call and webcast to discuss financial results the same day at 4:30 p.m. Eastern Time. Analysts, investors, and media can access the live webcast on the Azenta website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.